Introduction
The pathogenesis of acute coronary syndromes (ACS) is complex and its full knowledge still remains in fieri. In the past decades, the 'holy grail' of the 'vulnerable plaque' has driven extensive research. However, recent observations suggest that mechanisms of ACS are multiple and not necessarily associated with a vulnerable plaque phenotype. [1] [2] [3] [4] Indeed, coronary erosion is responsible for about one-third of ACS and typically develops at the site of a fibrotic plaque whereas about one-fifth of patients with ACS do not present fissure nor erosion suggesting functional alterations. 5, 6 The main driver of plaque rupture (PR) is considered inflammation as plaque inflammation may cause PR through the release of metalloproteinase and the inhibition of collagen synthesis. 3, 7, 8 This hypothesis is in keeping with data showing higher values of C-reactive protein (CRP) a sensitive marker of inflammation in patients with ACS as compared with patients with chronic stable angina. 9 Yet, CRP levels are normal in about a half of ACS patients, 10 suggesting that inflammation is probably involved in PR in a subset of patients only. In the last decade, studies performed by optical coherence tomography (OCT) have allowed us to shed new light on the pathologic substrate of ACS. 11, 12 In particular, OCT allows establishing the severity of plaque inflammation by assessing macrophage density. Although histology remains the best methodology for the evaluation of macrophages, OCT has been shown to be able to detect the presence of macrophages in plaques with thin fibrous cap. [13] [14] [15] Obviously, chronic low-grade inflammation associated with atherosclerosis is difficult to be detected by OCT, whereas enhanced macrophage accumulation in unstable plaques might be more easily detected. Thus, the purpose of this retrospective study was two-fold: (i) to assess whether patients with PR as culprit lesion of ACS represent a homogeneous population characterized by plaque inflammation as assessed by OCT and (ii) to establish whether raised systemic levels of inflammatory markers predict inflammation at the site of PR.
Methods
Between January 2012 and November 2014, a total of 130 consecutive patients with ACS who underwent OCT imaging of de novo culprit lesions in native coronary artery at our Institution (Agostino Gemelli Hospital, Catholic University of the Sacred Heart, Rome) were considered for inclusion in this retrospective study. Exclusion criteria were represented by significant hepatic or renal dysfunction, evidence of malignant disease or acute or chronic inflammatory disease, less than 18 or more than 80 years old, cardiogenic shock. According with these features, 14 patients were excluded. Among the remaining 116 patients we excluded also eight patients due to poor image quality caused by a large overlying thrombus or residual luminal blood. Eventually, 108 patients were enrolled in our study. Out of these, 56 patients presented, at OCT analysis, an image of PR as cause of coronary instability, thus representing the final population of our study. Patients were divided into two cohorts according to the presence, or not, of macrophage infiltration (MØI) qualitatively assessed by OCT ( Figure 1A) . Informed consent was obtained from all individual participants included in the study, and the study was approved by the Ethics Committee of our Institution. Patients with ST elevation (STE) ACS had chest pain, new persistent STE, cardiac troponin T rise and fall, and/or new regional wall motion abnormalities. Patients with No-ST elevation (NSTE) ACS had at least two episodes of angina at rest or one episode lasting >20 min during the preceding 48 h and normal levels (unstable angina) or raise and fall (NSTE-myocardial infarction, NSTEMI) of high sensitivity troponin T levels. Culprit lesion was identified by means of angiography, electrocardiographic ST-segment alterations, and/or regional wall motion abnormalities on echocardiographic assessment. Accordingly with the guidelines, all STE-ACS patients were treated with aspirin (300 mg) together with a P2RY12 inhibitor (clopidogrel 600 mg, prasugrel 60 mg, and ticagrelor 180 mg), whereas all patients with NSTE-ACS received aspirin (250 mg i.v. loading dose, followed by aspirin 75-100 mg daily) and received a loading dose of a thienopyridine (clopidogrel 600 mg and ticagrelor 180 mg) and fondaparinux or enoxaparin. In all patients, cardiovascular risk factors were carefully examined, including family history of early coronary artery disease (first-degree relative with a history of myocardial infarction <60 years), diabetes mellitus [fasting blood glucose > 126 mg/dL or treated diabetes mellitus (intake of a diabetic diet or oral hypoglycaemic agents), according to the new ADA criteria 16 ], hypercholesterolaemia (total cholesterol > 200 mg/dL or treated hypercholesterolaemia), smoking (current), and hypertension (systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg or treated hypertension). Body mass index was also obtained. Routine laboratory data, including full blood count, serum creatinine, glomerular filtration rate, glycaemia, lipid profile, fibrinogen, admission creatinkinase, and hs-troponin T were also collected. Medications taken on admission were recorded.
Procedural data
Coronary angiography was performed via the trans-radial or transfemoral approach with the use of a 6F or 7F sheath. Unfractionated heparin (initial weight-adjusted intravenous bolus of 60 IU/kg, with repeat boluses to achieve an activated clotting time of 250-300 s) was administered in all patients. 17 The use of intracoronary or intravenous platelet IIb/IIIa inhibitors was left to the operators' discretion, as well as manual thromboaspiration A 0.014 inch guidewire was placed distally in the target vessel and an intracoronary injection of 200 mg of nitroglycerin was performed. Culprit lesions were classified as complex or non-complex lesions based on their angiographic appearance using criteria published by Ambrose et al. 18 Non-complex lesions included: (i) concentric (symmetric and smooth narrowing) and (ii) type I eccentric (asymmetric stenosis with smooth borders and a broad neck). Complex lesions were defined as (i) type II eccentric (asymmetric stenosis in the form of a convex intraluminal obstruction with a narrow base due to !1 overhanging edges or extremely irregular or scalloped borders, or both), (ii) multiple irregularities (!3 serial and closely spaced severe obstructions or severe diffuse irregularities), and (iii) intraluminal filling defect or haziness suggestive of thrombus.
OCT image analysis
Frequency domain OCT (FD-OCT) images were acquired by a commercially available system (C7 System; LightLab Imaging Inc./St Jude Medical, Westford, MA) connected to an OCT catheter (C7 Dragonfly; LightLab Imaging Inc./St Jude Medical), which was advanced to the culprit lesion. The FD-OCT run was performed using the integrated automated pullback device at 20 mm/s. OCT was performed after vessel reopening with thrombus aspiration and/or gentle pre-dilatation. During image acquisition, coronary blood flow was replaced by continuous flushing of contrast media directly from the guiding catheter at a rate of 4 mL/s with a power injector, in order to create a virtually blood-free environment. 19 OCT image analysis was performed offline by two expert investigators (G.S. and H.R.) who were blinded to laboratory values. When there was discordance, a consensus was obtained with a third investigator (R.V.) Optical coherence tomography analysis was conducted along the entire OCT pullback in order to select patients with PR, according to culprit lesion morphology and to collect additional features. In addition, within the same vessel, all the angiographic mild or moderate lesions (more than 30% stenosis) that were remote from the culprit site were analysed. A multifocal distribution of coronary disease was defined as the presence of at least one remote mild or moderate lesion in each analysed vessel.
Minimal lumen area was evaluated along the length of the target lesion. PR was defined as the presence of fibrous cap discontinuity leading to a communication between the inner (necrotic) core of the plaque and the lumen. 13, 19 Tissue characteristics of underlying plaque were defined with previously established criteria. 13, 19 The presence of calcified (signal-poor region with defined borders), fibrous (homogeneous, signal-rich region), and lipid (signal-poor region with diffuse borders) plaques was recorded.
Calcifications within plaques were identified by the presence of welldelineated, low back-scattering heterogeneous regions. 19 . Thrombus was defined as an irregular mass protruding into the lumen or adjacent to the luminal surface. The thinnest part of the fibrous cap was measured three times, and the average value was calculated. In PR, residual fibrous cap was identified as a flap between the lumen of coronary artery and the cavity of plaque, and its thickness was measured at the thinnest part. Thin-cap fibroatheroma (TCFA) was defined as a plaque with lipid content in !2 quadrants and the thinnest part of a fibrous cap measuring 65 mm. 19 Microchannels were defined as non-signal tubuleluminal structures without a connection to the vessel lumen, recognized on more than three consecutive cross-sectional OCT images. 13 In the culprit segment, the presence of TCFA other than the culprit lesion, calcifications, and microchannels was assessed. Moreover, the length of calcified vessel was assessed as the sum of the calcified plaque longitudinal lengths (mm) along the imaged vessel. The length of lipid vessel was assessed as the sum of the lipid plaque longitudinal lengths (mm) along the imaged vessel. The cross-section that had the highest quadrant number and the greatest arc of calcium or lipids was recorded together with the minimal fibrous cap thickness.
Macrophage analysis
In order to classify patients according to the presence of local inflammation at the level of coronary plaques, we assessed the presence of MØI in the culprit and remote lesions by OCT. Patients were divided into two cohorts according to the presence, or not, of MØI, assessed by OCT in PR applying a two-step method.
The first step of our method was the qualitative identification of the region of interest (ROI) on raw OCT data. In particular, ROI was classified into three main regions: 20 ing as signal-rich, distinct, or confluent punctate regions that exceed the intensity of background speckle noise and generate a backward shadowing. As the attenuating speckled areas might be thrombus obscuring underlying lesion pathology, we chose to eliminate lesions containing a large thrombus from the data set. Moreover, median filtering was performed with a 3 Â 3 square kernel to remove speckle noise. In the second step, a quantitative analysis was performed on the selected ROIs by measuring the normalized standard deviation (NSD) known to have a high degree of positive correlation with histological measurements of macrophage content. 14, 15 In particular, by using a dedicated software provided by St Jude Medical for tissue characterization, NSD was measured for each pixel within each cap using a 125 mm 2 window centred at the pixel location:
NSDðx; yÞ ¼ ½rðx; yÞ125 lm 2 =ðSmax À SminÞ Â 100;
where NSD(x,y) is the NSD of the OCT signal at pixel location (x,y), Smax is the maximum OCT image value, and Smin is the minimum OCT image value. Pixels within the (125 Â 125) mm 2 window that did not overlap with the segmented cap were excluded. For each image, macrophage density was assessed as the average of three NSD values within the ROI (mean NSD), analysing the selected frames showing the best quality of MØI.
Blood test
Venous blood samples were drawn from the forearm before coronary angiography with the use of standard venipuncture. Collected samples Mechanisms of plaque rupture were immediately placed on ice and stored at À80 C until assayed, then sent to core laboratory (Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy) and centrally analysed. Serum highsensitivity CRP was measured with the use of a latex-enhanced immunophelometric assay by BN II analyser (Siemens Healthcare Diagnostics, Deerfiled, IL, USA) and expressed as mg/L, with a lower detection limit of 0.175 mg/L and inter-assay coefficient of variation of 7.6%.
Statistical analysis
The distribution of continuous variables was assessed by visual inspection of frequency histograms and with the use of the Shapiro-Wilk test. Continuous variables were expressed as mean 6 SD or median with interquartile range, if they followed a normal or non-normal distribution, respectively. Continuous variables were compared with unpaired t-test or Mann-Whitney U test, whereas categorical variables were compared using the v 2 test or Fisher's exact test, as appropriate. Correlations between variables were performed using the Pearson test. All variables were tested in a univariable model and then entered in the multivariable model if P-value was <0.05. Binomial logistic regression analysis was performed. In order to address skewed data, logarithmic transformation was applied directly from the software. Intra-observer and inter-observer variabilities in the analysis of MØI in the fibrous cap were assessed by kappa measure of agreement. The software SPSS 17.0 (SPSS Italy, Florence, Italy) was used for statistical analyses.
Results

Plaque inflammation and clinical findings
Clinical, angiographic, and OCT data are reported in Table 1 and in Figure 1B . Fifty-six patients with ACS were enrolled, 20 (35.7%) presenting with STE-ACS and 30 (53.5%) with NSTEMI. The mean age of the overall population was 64 6 12 years, whereas 37 (66.2%) were males. Thirty-seven (66%) patients had MØI at the site of PR, whereas 19 (34%) patients had no evidence of MØI. Regarding the evaluation of MØI in PR, Kappa measures of agreement for intraobserver and inter-observer variabilities were 0.82 (P ¼ 0.0001) and 0.91 (P < 0.001), respectively. There were no differences in the medical treatment of the two cohorts of patients at admission. In particular, a high rate of statin therapy was detected in the both groups (86% for patients with MØI vs. 79% for patients without MØI, P ¼ 0.46). Patients with MØI showed a higher rate of CRP values >3 mg/dL as compared with those without MØI (92% vs. 47%, P ¼ 0.004). Accordingly, CRP absolute levels were higher in patients with MØI as compared with those without MØI (11.8 6 15.7 vs. 5.6 6 6.8, P ¼ 0.004). In contrast, patients without MØI had a higher rate of hypertension compared with those with MØI (89% vs. 59%, P ¼ 0.021).
Finally, in the cohort of the study presenting MØI and CRP values >3 mg/dL, STE-ACS patients showed a higher NSD compared with those with NSTEMI (7.0 60.59% vs. 6.26 6 0.59%, P ¼ 0.002).
Plaque inflammation and plaque morphology
Patients with MØI had a significantly higher rate of lipid-rich plaques as compared with those without MØI (86% vs. 50%, P ¼ 0.008). Moreover, patients presenting MØI in the culprit plaque showed a higher rate of multifocal disease as compared with those without MØI (59% vs. 10%, P < 0.001).
Of note, culprit plaques exhibiting MØI were associated with MØI in remote lesions along the same vessel in all except one patient (97%). In contrast, none of the patients without evidence of MØI at the site of the culprit plaque had evidence of MØI in remote lesions.
Finally, a positive correlation between NSD measured at the culprit lesions and CRP values was present within patients with MØI (R 2 ¼ 0.42, P ¼ 0.002). 
Predictors of MØI
Discussion
We demonstrate, for the first time, that patients with ACS and PR are a heterogeneous population; indeed, about two-thirds of patients had evidence of plaque inflammation by OCT whereas about onethird did not exhibit plaque inflammation. Of note, more than 90% of patients with inflamed PR had raised systemic levels of CRP, whereas raised levels of CRP were found in around 45% only of patients without evidence of plaque inflammation. Furthermore, inflamed PR had evidence of a more vulnerable phenotype as compared with noninflamed PR characterized by a high rate of lipid plaques and multifocal inflammation. Thus, taken together, these data suggest that in patients with ACS, PR might be caused by inflammatory or noninflammatory mechanisms. Pathological studies have suggested that inflammation involved in all steps of atherosclerosis and that it plays a key role in PR as enhanced local macrophage accumulation may favour rupture of the fibrous cap through the secretion of matrix metalloproteinases which weaken the fibrous cap, through the secretion of interferon-c which inhibits collagen synthesis as well as by promoting thrombus formation through the release of tissue factor. 21 Increased MØI within culprit lesions has been demonstrated in autopsy and in vivo studies of patients presenting with ACS [22] [23] [24] and macrophage density in the coronary plaque has been shown to be correlated with peripheral white blood count, 25 cup rupture, and positive remodelling. 26 Our data provide a mechanistic explanation of previous studies showing raised CRP levels in patients with ACS. Indeed, CRP levels correlated with MØI in PR in our population. Thus, higher CRP levels seem indeed to reflect macrophage accumulation in the culprit coronary plaque. Of note, in patients with inflammatory PR, macrophage density was higher in those presenting STE-ACS, compared with those with NSTEMI.
Interestingly, patients with MØI beyond having higher CRP levels had more frequently inflamed remote plaques in the same vessel. Of note, in the PROSPECT study in patients with ACS, major adverse cardiovascular events occurring during a 3-year follow-up were equally attributable to recurrence at the site of culprit lesions and to non-culprit lesions. 27 Moreover, a recent study from our group showed that patients with ACS presenting PR as culprit lesion have a worse prognosis compared with that of patients with intact fibrous cap. 28 Recurring events in non-culprit site may potentially occur more frequently in patients with PR and MØI, a hypothesis that needs to be confirmed in larger studies, analysing both PR and lesions, with strong clinical implications as that may prime a more aggressive treatment and a stricter follow-up. Of note, the pathobiology of erosion is different of that of fissure 29, 30 and probably needs different tools to be investigated. Yet, in this study about one-third of patients did not have evidence of inflammation at the site of PR. This subset of patients was characterized by a higher rate of hypertension as compared with those with inflamed PR, by lack of multifocal disease and by a lower rate of lipid plaques. All these features seem to identify a different pathogenetic mechanism of PR, perhaps related to enhanced local and/or mechanical stress. [1] [2] [3] In this setting, environmental, physical, or emotional stressors might be cause coronary instability by sympathetic nervous system activation and catecholamine release. 31, 32 Furthermore, Abela et al. 33 proposed that chemical-physical factors, including local saturation of cholesterol, temperature, pH, and hydration status, could alone or in various combinations lead to cholesterol crystallization with sudden and forceful volume expansion leading to plaque fissure and thrombosis. Finally, it is worth noting that, in our study, about 45% of patients without inflamed PR had raised levels of CRP. This might be related to the fact that CRP is a non-specific marker of inflammation and raised levels might be related to extra-coronary inflammatory stimuli including myocardial necrosis.
Limitation of the study
Our study presents important limitations. First, our study population is small and highly selected, thus precluding a reliable patient outcomes analysis as well as extrapolation to the whole population of patients with ACS. Nevertheless, our goal was simply to prove that 'not all plaque fissures are born equal'. It is likely that the prevalence of inflamed vs. non-inflamed plaque fissures is different in different populations. Furthermore, the cross-sectional and retrospective nature of the study precludes the understanding of the mechanisms resulting in different plaque types or the possible clinical implications of differing lesion types.
Second, thrombus rapidly attenuates the OCT signal, thus limiting accurate measurement of macrophage content. Although in principle it is possible to correct for the attenuation of the overlying thrombus, this correction method has not yet been validated against a gold standard. As a result, we chose to eliminate lesions containing a large thrombus from the data set. However, we cannot be sure that the attenuating speckled areas were indeed not small thrombus obscuring underlying lesion pathology.
Third, we cannot exclude that in some patients PR was iatrogenic being caused by thrombus aspiration. However, this phenomenon, if really relevant, may affect patients with STE-ACS that represented less than a half of our population, and thrombus aspiration was performed in 20% of patients only.
Moreover, if OCT has indeed shown good correlation in validation studies, one needs to keep in mind that intracoronary imaging findings are a suboptimal reflection of true histology, especially for MØI.
Of note, the differentiation of macrophages in ruptured plaques has not been sufficiently validated. Accordingly, in a recent OCT-fibroatheroma validation article, Nakano et al. 34 pointed out as the differentiation between fibrous cap vs. macrophages represents one of the substantial limitations of the OCT. Furthermore, although our evaluation of macrophages was based on the IWG-IVOCT, a recent article by Phipps et al. 35 suggested that the diagnostic accuracy of OCT for such bright spots with sharp attenuation is not specific for macrophages. In this context, histology remains the 'gold standard' to assess the presence of macrophages in coronary plaque. However, in pathological studies, the standard deviation of quantification of MØI resulted elevated, 21 thus suggesting the presence of some PR with abundant macrophages and other with sparse macrophages. Taken into account these data, OCT might represent an alternative method to broadly evaluate the presence of macrophages, thus characterizing inflammation severity of the plaque in vivo. Again, in this article, we pointed out a good agreement for intra-observer and inter-observer variabilities in the macrophage evaluation, thus showing a reproducibility of our method. Finally, other inflammatory biomarkers, in addition to the CRP, could be of further value to confirm the existence of systemic inflammation.
Conclusions
In conclusion, not all PR in patients with ACS are born equal. Indeed, PR might be caused by inflammatory or non-inflammatory mechanisms, both acting on the common low-grade chronic inflammatory background characterizing the atherosclerotic plaque. Future larger studies are required to evaluate whether these two mechanisms may portend different outcomes and need different forms of treatment.
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